Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- CORPORATE ROUNDUP NEWS IN BRIEF
September 13, 2004
- The Role of the PMDA Discussed: Jiho Symposium
September 13, 2004
- BUSINESS NEWS IN BRIEF
September 13, 2004
- BULLETUN
September 13, 2004
- CareNet, SSRI to Collaborate in Market Research, Info Supply
September 13, 2004
- Nippon Shinyaku's Trisenox Injection Recommended for Approval
September 13, 2004
- A Great Deal of Room for Growth: Mr Tanimura of So-Net M3
September 13, 2004
- Korosho Seeks 14.9% Boost in Budget Related to Science & Technology in FY2005
September 13, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 13, 2004
- PFSB to Request \10.26 Bil. with 1.7% Increase for FY2005 Budget
September 13, 2004
- Lifestyle Diseases No Longer Tending to Increase: JHA Survey
September 13, 2004
- GPs' Participation Needed for Recovery of Domestic Clinical Trials: OMA Seminar
September 13, 2004
- WORLD NEWS IN BRIEF
September 13, 2004
- Details Proposed for Advanced Services in Special Structural Reform Zone: Korosho
September 13, 2004
- Korosho's FY2005 Draft Budget Request Reaches \21.26 Trillion
September 6, 2004
- MEDICAL DEVICE NEWS IN BRIEF
September 6, 2004
- METI's FY2005 Draft Budget Request Seeks 14.8% Increase
September 6, 2004
- NEW PRODCUTS
September 6, 2004
- Medical Costs Up 2.1% to \30.8 Trillion in FY2003
September 6, 2004
- DIAGNOSTIC NEWS IN BRIEF
September 6, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…